CureVac sues Moderna for patent infringement over COVID-19 vaccines

CureVac Announces Voting Results of Extraordinary General Meeting

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac Announces Voting Results of General Meeting

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BioNTech to acquire CureVac in $1.25 billion all-stock deal

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

European Patent Office declares CureVac mRNA patent valid

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents